X
Story Stream
recent articles

The phrase "terminal disclaimers" has become something of a bête noire in today's patent debate -- and particularly in the realm of pharmaceutical patents. According to critics, the mere use of these legal mechanisms -- which link related patents to a common expiration date and owner -- is evidence that some form of abuse is afoot.

Their assumption is that terminal disclaimers let inventors obtain duplicative patents on a single invention to block competitors from entering the market by elongating the period of protection.

It's an increasingly popular view. It's also deeply mistaken. Terminal disclaimers aren't a loophole for obtaining duplicative patents. Rather, they ensure that patents covering different inventions associated with complex products such as medicines can be granted without unjustifiably extending the patent term.

At their most basic, terminal disclaimers allow our patent system to manage the messy realities of technological innovation. To see how, it's important to understand that research and development is an iterative process.

Following an early discovery, an inventor might file an initial patent to protect the core breakthrough -- the key insight that makes a new product, treatment, or technology possible. But that's not the end of the story.

An initial patent may not capture every aspect of an invention with perfect precision. So, as the process continues, applicants may seek additional patents that describe different aspects of the invention or define it more exactly.

If a patent examiner finds that a later application overlaps too closely with an earlier patent, the inventor can agree to tie the two patents together under a terminal disclaimer. When this happens, the newer patent must expire at the same time as the older one.

In other words, terminal disclaimers do not prolong patent protection. They do the opposite -- ensuring that later patents don't outlast the initial patent to which they are linked. In this way, the patent system permits inventors to continue refining how an invention is described and protected while preventing them from extending the duration of their exclusivity.

This shouldn't be controversial. And yet, remarkably, this innocuous legal mechanism has invited harsh criticisms in recent years.

A recent research letter in the Journal of the American Medical Association, for example, argued that terminal disclaimers help drug manufacturers build sprawling patent portfolios that can impede biosimilar competition.

Such criticisms treat terminal disclaimers as if they were evidence that inventors are obtaining duplicative patents in order to extend their exclusivity. In reality, terminal disclaimers were developed to prevent exactly that outcome.

Once that point is understood, the broader criticism begins to unravel. For one, the USPTO has studied the relationship between pharmaceutical patent portfolios and generic competition and found no clear connection between the number of patents associated with a medicine and the timing of generic entry.

Nor does filing a terminal disclaimer exempt an application from standard USPTO examination. The application still must satisfy the same statutory requirements that otherwise apply before any patent can issue.

Policymakers should keep these points in mind as they consider proposals to restrict the use of terminal disclaimers. Such reforms would alter a long-standing feature of patent practice that allows applicants to protect all aspects of an invention while limiting how long a later patent on that invention can remain in force.

Terminal disclaimers are not evidence that patent owners are somehow gaming the system in order to extend their exclusivity. In fact, their very purpose is to limit how long a later patent can last. Those who treat these legal safeguards as instruments for prolonging patent protection misunderstand what terminal disclaimers actually do.

Paul Michel served on the United States Court of Appeals for the Federal Circuit from 1988 to his retirement in 2010, and as its chief judge from 2004 to 2010.

Kathleen O'Malley served on the United States Court of Appeals for the Federal Circuit from 2010 to 2022 and the U.S. District Court for the Northern District of Ohio from 1994 to 2010. Both currently serve as board members of the Council for Innovation Promotion.

Comment
Show comments Hide Comments